To Evaluate the Efficacy of Supplementation With L. Reuteri + Vit. D3 in Asthmatic Children
To Evaluate the Efficacy of Supplementation With L. Reuteri + Vit. D3 in Asthmatic Children
The purpose of this project is to evaluate in a randomized clinical trial, double-blind,
 controlled, the effects of a dietary supplement containing Lactobacillus reuteri DSM 17938
 and vitamin D3 in reducing bronchial inflammation and improve asthma control in patients in
 children with mild / moderate persistent asthma .
To evaluate if the supplementation for three months with Lactobacillus reuteri DSM 17938 (108
 CFU) + Vitamin D3 (400 IU) result in a reduction of the degree of allergic bronchial
 inflammation, measured with the Fractional exhaled nitric oxide (FeNO) and with a series of
 markers of bronchial inflammation (measured at 'beginning and at the end of the treatment on
 exhaled condensate): Interleukin 2(IL-2); Interleukin 4 (IL-4); Interleukin 10(IL-10);
 Interferon γ (IFN-γ).
Inclusion Criteria:

 -  Patients aged between 6 and 14 years old, of both sexes

 -  Diagnosis of mild / moderate persistent asthma (GINA step 2/3)

 -  Allergy mite (Dermatophagoides farinae and pteronyssinus + + + / + + + +)

 -  Levels of vitamin 25 (OH) D <30 ng / ml

 -  Signature of the informed consent of one parent or a legal representative

 Exclusion Criteria:

 -  Cardiovascular disease or systemic

 -  anatomical abnormalities

 -  Other respiratory diseases

 -  Taking probiotics and / or prebiotics in the previous 2 weeks

 -  Taking vitamin D or systemic corticosteroids within 4 weeks

 -  Participation in other clinical trials